Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2025.07.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Andrea Riccardo Filippi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Istituto Nazionale dei Tumori di Milano, Milan, Italy; Department of Oncology, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: AstraZeneca PLC.
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) is a leading cause of death for cancer worldwide. Standard treatment for patients for whom surgical resection is not feasible is concurrent (PACIFIC regimen) or sequential (PACIFIC-like regimen) chemoradiotherapy with platinum-based doublet chemotherapy followed by durvalumab maintenance. The progression-free survival (PFS) rate after the PACIFIC regimen was 55.3% at 12 months, with the primary site of recurrence being intrathoracic. In retrospective studies, a relevant proportion of patients presented a combination of intrathoracic failure and limited extra-thoracic metastatic disease. For patients with local progression only, or with loco-regional progression and limited metastatic burden, the use of chemotherapy or other agents without the addition of a local therapy may represent a missed opportunity for a second curative intent treatment approach. The AUSTRAL trial, a phase II, interventional, multicenter, single-arm, study (ClinicalTrials.gov identifier, NCT06680050) aims to investigate the combination of thoracic irradiation ± Stereotactic Body Radiation Therapy (SBRT) to oligometastatic sites followed, after 2 to 4 weeks, by durvalumab and ceralasertib, administered until progression or severe toxicity. The study population will include 21 stage III NSCLC patients with loco-regional relapse after >12 months from the end of CRT ± ≤3 metastatic lesions following PACIFIC/PACIFIC-like regimens. The study will last approximately 40 months and involve 7 Italian and 2 Swiss sites. Primary hierarchical endpoints are safety, assessed by the continuous toxicity monitoring approach, and efficacy, assessed by PFS. Secondary endpoints are objective response rate (ORR), 6- and 12-month PFS and OS rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Oncology Department, Istituto Nazionale dei Tumori di Milano, Milan, Italy; Department of Oncology, University of Milan, Milan, Italy.
- Clinical Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. Electronic address: eliana.rulli@marionegri.it.
- Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
- Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Medical Oncology Department, Hopitaux Universitaires de Geneve, Geneve, Switzerland.
- Clinical Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Förderung
- AstraZeneca PLC
Zitieren
APA
Filippi, A. R., Rulli, E., Signorelli, D., Willmann, J., Durham, A., De Simone, I., Santoni, A., Galli, F., Carlucci, L., Torri, V., Lo Russo, G., Addeo, A., & Guckenberger, M. (2025). Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.07.006
Vancouver
Filippi AR, Rulli E, Signorelli D, Willmann J, Durham A, De Simone I, et al. Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.07.006
BibTeX
@article{Filippi2025,
author = {Filippi, Andrea Riccardo and Rulli, Eliana and Signorelli, Diego and Willmann, Jonas and Durham, Andrè and De Simone, Irene and Santoni, Anna and Galli, Francesca and Carlucci, Luciano and Torri, Valter and Lo Russo, Giuseppe and Addeo, Alfredo and Guckenberger, Matthias},
title = {Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2025.07.006}
}
EUVIMED